Table 1.

Population Characteristics

Gender	Cases	% Cases	Ondansetron	%	Odds for Ondansetron
female	249909	56.6	131667	52.7	1.1
male	191654	43.4	91782	47.9	0.9
NA	82	0.0	23	28.0	0.4
Age	Cases	% Cases	Ondansetron	%	Odds for Ondansetron
Under 1	6357	1.4	1354	21.3	0.3
1–18	35881	8.1	20573	57.3	1.3
19 – 49	159002	36.0	90636	57.0	1.3
50 – 64	116869	26.5	58614	50.2	1.0
65 – 79	96274	21.8	42501	44.1	0.8
80+	27252	6.2	9792	35.9	0.6
NA	10	0.0	2	20.0	0.2
Anesthetic	Cases	% Cases	Ondansetron	%	Odds for Ondansetron
General	277112	62.7	191822	69.2	2.2
Neuroaxial	31208	7.1	8962	28.7	0.4
Regional	10710	2.4	2046	19.1	0.2
MAC	89241	20.2	15943	17.9	0.2
NA	33374	7.6	4699	14.1	0.2
ASA class	Cases	% Cases	Ondansetron	%	Odds for Ondansetron
1	42143	9.5	27192	64.5	1.8
2	153117	34.7	88204	57.6	1.4
3	133965	30.3	68478	51.1	1.0
4	39382	8.9	10244	26.0	0.4
5	1407	0.3	29	2.1	0.0
NA	71631	16.2	29325	40.9	0.7
Insurance	Cases	% Cases	Ondansetron	% utilized	Odds for Ondansetron
Commercial	97443	22.1	55654	57.1	1.3
MEDICAID	25865	5.9	11245	43.5	0.8
Medicare	51441	11.6	23798	46.3	0.9
SELF	1585	0.4	922	58.2	1.4
NA	265311	60.1	131853	49.7	1.0

Table 1 details the population characteristcs and ondansetron utilization in the NACOR dataset (n = 441645) reported by 6 unique institutions in the Public Use File of the Anesthesia Quality Institute, enriched with antiemetic utilization and insurance provider information. The first column tabulates patient or case characteristics. The second column list the number of cases with that characteristic (and the third column in brackets the corresponding case frequency in percent). The fourth column tabulates the number of cases with antiemetic utilized for that characteristic (and the fifth presents the corresponding antiemetic utilization in percent).